Skip to main content Accessibility help
×
Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-23T05:56:54.799Z Has data issue: false hasContentIssue false

Debate 10A - Patients with Advanced Ovarian Cancer who are 75 Years Old and Above Should Routinely be Treated with Neoadjuvant Chemotherapy?

Yes

from Section III - Ovarian Cancer

Published online by Cambridge University Press:  20 July 2023

Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

Age is an independent predictor of survival in advanced ovarian cancer. However, inadequate therapy appears to be a driver for decreased survival among elderly patients with cancer. Multiple randomized control trials have demonstrated equivalent oncologic outcomes with neoadjuvant chemotherapy compared to primary cytoreduction with reduced perioperative complications and mortality, decided by a gynecologic oncology surgeon. A national database study demonstrates an improvement in the receipt of both surgery and chemotherapy over time with high adoption of NACT contributing to an improvement in outcomes. In an elderly population, NACT results in a 70% reduction in perioperative mortality. All patients 75 years of age or older with one medical co-morbidity are the highest risk group for postoperative mortality (average 30-day post-operative mortality of 13% with primary surgery). These patients likely will benefit the most from NACT and should be considered routine practice for elderly patients with advanced ovarian cancer.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Coleridge, SL, et al. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev 2019;10:CD005343. https://doi.org/10.1002/14651858.CD005343.pub4Google Scholar
Melamed, A, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all-cause mortality: quasi-experimental study. Br Med J 2018;360:5463.CrossRefGoogle ScholarPubMed
Thrall, MM, et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011;118(3):537547. https://doi.org/10.1097/AOG.0b013e31822a6d56CrossRefGoogle ScholarPubMed
Tew, W. Ovarian cancer in the older woman. J Geriatr Oncol 2016;7(5):354361.CrossRefGoogle ScholarPubMed
Kumar, A, et al. Functional not chronologic age: frailty index predicts outcomes in advanced ovarian cancer. Gynecol Oncol 2017;147(1):104109.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×